What’s Propelling Galectin Therapeutics Inc (NASDAQ:GALT) After Higher Shorts Reported?

Galectin Therapeutics, Inc. (NASDAQ:GALT) Logo

Investors sentiment decreased to 1.06 in 2018 Q4. Its down 0.23, from 1.29 in 2018Q3. It worsened, as 8 investors sold Galectin Therapeutics, Inc. shares while 10 reduced holdings. 10 funds opened positions while 9 raised stakes. 4.77 million shares or 7.28% less from 5.15 million shares in 2018Q3 were reported.
Citadel Advsr Limited Liability Corporation stated it has 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Neuberger Berman Grp Limited Liability Com has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Morgan Stanley, a New York-based fund reported 62,205 shares. Moreover, Vanguard Group Inc has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 1.43 million shares. Susquehanna Intll Group Incorporated Limited Liability Partnership reported 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). 19,021 were reported by Cetera Advisor Netwr Ltd. Northern Trust Corporation holds 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT) or 86,932 shares. Lpl Fin Limited Liability holds 0% or 28,877 shares in its portfolio. Boothbay Fund Mgmt Ltd Liability Co invested in 30,562 shares. Barclays Public Ltd Company holds 0% or 174,603 shares. Group Inc One Trading L P has 4,965 shares for 0% of their portfolio. Bluecrest Management holds 0.01% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 31,614 shares. Optimum Inv holds 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 20 shares. California Public Employees Retirement Sys reported 23,450 shares. Wells Fargo And Mn accumulated 0% or 8,629 shares.

Since September 25, 2018, it had 5 insider purchases, and 1 sale for $128,476 activity. ELDRED KARY bought $12,200 worth of stock or 2,000 shares. The insider Uihlein Richard E bought $250,559. $4,484 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) shares were bought by LEWIS JOEL. FREEMAN KEVIN D had bought 1,500 shares worth $6,428.

The stock of Galectin Therapeutics Inc (NASDAQ:GALT) registered an increase of 7.42% in short interest. GALT’s total short interest was 3.40M shares in March as published by FINRA. Its up 7.42% from 3.17 million shares, reported previously. With 309,900 shares average volume, it will take short sellers 11 days to cover their GALT’s short positions. The short interest to Galectin Therapeutics Inc’s float is 9.71%.

The stock increased 0.43% or $0.02 during the last trading session, reaching $4.7. About 190,899 shares traded. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 31.58% since March 15, 2018 and is uptrending. It has outperformed by 27.21% the S&P500.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $214.09 million. The companyÂ’s lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Ratings Coverage

Among 2 analysts covering Galectin Therapeutics (NASDAQ:GALT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Galectin Therapeutics had 4 analyst reports since February 13, 2019 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, March 7 by H.C. Wainwright. The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) has “Buy” rating given on Thursday, March 7 by FBR Capital.

More notable recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: Streetinsider.com which released: “Form 10-K BIOXYTRAN, INC For: Dec 31 – StreetInsider.com” on March 13, 2019, also Fool.com with their article: “3 Stocks That Could Double Your Money – Motley Fool” published on July 26, 2018, Globenewswire.com published: “Galectin Therapeutics to Present at the 2nd Annual Anti-Fibrotic Drug Development Summit – GlobeNewswire” on November 19, 2018. More interesting news about Galectin Therapeutics, Inc. (NASDAQ:GALT) were released by: Benzinga.com and their article: “Benzinga’s Top Upgrades, Downgrades For February 13, 2019 – Benzinga” published on February 13, 2019 as well as Seekingalpha.com‘s news article titled: “Galectin Therapeutics: Lackluster Trial Results, Bad Credit Line Somehow Jump Stock 300% – Seeking Alpha” with publication date: January 29, 2018.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Institutional Positions Chart